Analysis Tools
mortality/aging
|
• without doxycycline treatment median survival is 82 days, with doxycycline treatment the improves to 145 days
|
neoplasm
|
• in the absence of doxycycline, lymphoblastic leukemia is seen by 2 weeks of age
• in 5 - 7 week old triple transgenics with lymphoblastic leukemia doxycycline treatment resulted in normalization of the WBC count and restoration of normal hematopoiesis
|
|
• bulky B cell derived lymphomas, similar to those in Tg(IghMyc)22Bri single transgenics, are seen in older triple transgenics after treatment with doxycycline
|
behavior/neurological
|
• transgenics with leukemia are lethargic, doxycycline treatment returns activity levels to normal
|
hematopoietic system
|
• in the absence of doxycycline, mutants develop an enlarged spleen with doxycycline treatment the spleen returns to its normal size
|
immune system
|
• in the absence of doxycycline, mutants develop an enlarged spleen with doxycycline treatment the spleen returns to its normal size
|
growth/size/body
|
• in the absence of doxycycline, mutants develop an enlarged spleen with doxycycline treatment the spleen returns to its normal size
|
